Transaera, Inc. | $10,500,000 | (Nov 5, 2024)
Algebrik AI | $4,000,000 | (Nov 5, 2024)
Further | $4,100,000 | (Nov 5, 2024)
ImmuONE
United Kingdom
- Hatfield, Hertfordshire
- 26/10/2023
- Unknown
- $2,423,000
ImmuONE specialises in human alveolar macrophage responses, epithelial cell culture platforms and testing services. Our respiratory tissue models closely resemble lung physiology to provide relevant, reliable, and reproducible results.
ImmuONE is partnered with the industry and academia to develop sustainable technologies for the future to support human-relevant, mechanistic driven safety assessments and develop animal product-free cell models.
We offer a range of standard and bespoke assessments for inhalation safety assessment needs. ImmuONE provides innovative solutions for inhalation toxicology, irritation sensitization, alveolar clearance, inflammation and can tailor to your inhalation safety assessment needs.
We invite you to learn more about how our products and services can help your business by visiting our website: www.immuone.com
Follow us on Twitter:
@ImmuONE
- Industry Biotechnology
- Website http://www.immuone.com/
- LinkedIn https://www.linkedin.com/company/immuone/about/
Related People
Abigail MartinFounder
United Kingdom -
London, England
Scientist turned entrepreneur in biotech!
Previous winner of INNOVATE UK funding and sponsored programme ICURe 2019! In 2018, I travelled the world talking with the inhalation and allergy industries about standardising In Vitro technologies for safety assessments and toxicology outcomes. With support from INNOVATE UK, UH & Santander, I embarked on the journey from scientist to CEO of a biotech start-up!
For me, it’s about applying research to the outside world, taking science from the bench side and gauging the innovative potential for commercialisation. I dream big because ICURe SETsquared awarded me the opportunity to combine my love of science with my ridiculously good organisation and management skills.
Since June 2020, we have developed and launched multiple human-lung and immune in-vitro products of the lower airway. Our services offer standard testing and advanced assays to assist our clients with questions of uncertainty, ultimately helping them in their decisions to get products to market. We have also grown our team from 2 to 14 brilliant individuals (go and see for yourself!)
Connect with me over LinkedIn!
Specialities: toxicology, biotechnology and innovation
Cintoo | $40,246,701 | (Nov 5, 2024)
Advex AI | $3,500,000 | (Nov 5, 2024)
Insider. | $500,000,000 | (Nov 5, 2024)
OpenOrigins | $4,500,000 | (Nov 1, 2024)
MealMe, Inc. | $8,000,000 | (Nov 1, 2024)
Persperity Health, Inc | $1,000,000 | (Nov 1, 2024)
Persana AI | $2,300,000 | (Nov 1, 2024)
Definition Health | $7,412,756 | (Nov 1, 2024)